AMEV-Applied Molecular Evolution Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMEV-Applied Molecular Evolution

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who started this subject	4/16/2001 12:54:37 AM
From: tuck	Read Replies (2) of 164

Correction: no milestone for PI. Found it in the S-1: >>6.12(a) MEDIMMUNE shall pay to IXSYS the following milestone payments upon the occurrence of the following events with respect to a PRODUCT and all or a portion of such milestone payment may be made by the purchase of common stock of IXSYS in accordance with Section 6.12(d): A. PRODUCT for * indication EVENT PAYMENT (1) Initiate Phase II Clinical Trial * (2) Initiate a Phase III Clinical Trial * (3) Submission of a Biologics License Application in the United States or an equivalent for Europe (or any country in Europe) or Japan * (4) Approval of a Biologics License Application in the United States * (5) Approval to sell in Europe (or any country in Europe) including pricing approvals * (6) Approval to sell in Japan including pricing approvals * B. PRODUCT for an indication other than * indication. EVENT PAYMENT (1) Initiate Phase II Clinical Trial * (2) Initiate a Phase III Clinical Trial * (3) Submission of a Biologics License Application * CONFIDENTIAL MATERIAL REDACTED AND FILED SEPARATELY WITH THE COMMISSION -11- <PAGE> 12 in the United States or an equivalent for Europe (or any country in Europe) or Japan * (4) Approval of a Biologics License Application in the United States * (5) Approval to sell in Europe (or any country in Europe) including pricing approvals * (6) Approval to sell in Japan including pricing approvals * C. Sales Milestones EVENT PAYMENT (1) Cumulative NET SALES of PRODUCTS in a calendar year exceeds * * (2) Cumulative NET SALES of PRODUCTS in a calendar year exceeds * * (b) Each of the * milestones shall be paid * whereby the total milestone payment for all PRODUCTS is: (i) * under Section 6.12(a) A ; (ii) * under Section 6.12(a) B ; and (iii) * under Section 6.12(a) C. (c) The milestone payments under Section 6.12(a) are due and payable sixty (60) days after the applicable milestone occurs. (d) At its option, MEDIMMUNE may make the milestone payment due under Section 6.12(a) in the form of a purchase of common stock of IXSYS on the date the applicable milestone payment is due in a dollar amount equal to the applicable milestone payment<< . . . (further boilerplate concerning milestones snipped) Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next